Metric Finance
LearnFAQ
LearnFAQ

Learn / CLBT

NASDAQ: CLBT

Cellebrite DI Ltd. (CLBT) stock, explained like you're 5

Cellebrite DI Ltd. trades on the Nasdaq under the ticker CLBT. It is a mid cap company in the prepackaged software industry, part of the technology sector, with a market value of about 2.8 billion dollars.

Ticker
CLBT
Exchange
Nasdaq
Sector
Technology
Industry
Prepackaged Software
Size
Mid cap, about 2.8 billion dollars

Is Cellebrite DI Ltd. a small, medium or large cap company?

No. Cellebrite DI Ltd. is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 2.8 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Cellebrite DI Ltd. makes money

  • Selling software, hardware or cloud services, often as a subscription.
  • Charging businesses and consumers for products they use every day.
  • Licensing its technology and selling related services.

What moves CLBT stock

  • How fast sales are growing, especially in cloud and AI.
  • New product launches and customer wins.
  • Competition, regulation and how much the company spends on research.

In the news lately

  • Cellebrite DI Ltd. Stock Grades | CLBT (Barron's)
  • Cellebrite DI (NasdaqGS:CLBT) Stock Forecast & Analyst Predictions (Simply Wall Street)
  • Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap? (Yahoo Finance)
  • Cellebrite DI Ltd. (CLBT) Securities Investigation Notice Levi & Korsinsky (PR Newswire)
  • Pertento Partners LLP Adds Cellebrite DI Ltd (CLBT) Shares Lo (GuruFocus)

Follow CLBT in your daily brief

Each trading day at 5 PM ET we post what happened to Cellebrite DI Ltd. and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow CLBT

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Cellebrite DI Ltd. stock

What does Cellebrite DI Ltd. do?

Cellebrite DI Ltd. trades on the Nasdaq under the ticker CLBT. It is a mid cap company in the prepackaged software industry, part of the technology sector, with a market value of about 2.8 billion dollars.

What is the ticker symbol for Cellebrite DI Ltd.?

Cellebrite DI Ltd. trades under the ticker CLBT on the Nasdaq.

What is Cellebrite DI Ltd.'s market cap?

Cellebrite DI Ltd. is a mid cap stock with a market cap of about 2.8 billion dollars.

How does Cellebrite DI Ltd. make money?

Selling software, hardware or cloud services, often as a subscription. Charging businesses and consumers for products they use every day. Licensing its technology and selling related services.

What moves CLBT stock?

How fast sales are growing, especially in cloud and AI. New product launches and customer wins. Competition, regulation and how much the company spends on research.

How can I follow CLBT stock every day?

Add CLBT to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow CLBT daily

A free brief on Cellebrite DI Ltd. and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • SAP · Sap SE
  • NTES · NetEase
  • MSTR · Strategy
  • TEAM · Atlassian

Similar stocks

  • SAPSap SE
  • NTESNetEase
  • MSTRStrategy
  • TEAMAtlassian

Compare CLBT: CLBT vs SAP, CLBT vs NTES, CLBT vs MSTR

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed